May 2017
argenx
Issuer's Adviser
USD 115 million
Initial Public Offering on NASDAQ

argenx

argenx is a clinical stage biopharmaceutical company creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases

  • Kempen & Co acted as adviser to the issuer in this transaction